Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

The president has said the law is unfair to U.S. businesses. But lawyers say weakening it could end up costing corporate ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

U.S. Senator Tammy Baldwin (D-WI) joined a group of her colleagues in introducing the Capping Prescription Costs Act, ...

Wide-moat GE HealthCare, or GEHC, is a top three global leader in the medical imaging market. It has a firmly established footprint in hospitals and health networks around the world, and it is ...

Those companies which are able to quickly improve productivity can benefit, but those which lag behind will get hurt. So, ...

These customized levies, expected to be finalized by April, are designed to rebalance trade relationships and target unfair ...

After a telehealth company's Super Bowl commercial sparked nationwide debate about pharmaceutical safety and advertising, one DSO executive is reflecting on what the controversy means for patient care ...

Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...